Abstract
Vaccination has become one of the most promising immunotherapeutic approaches in the prevention and treatment of Alzheimer’s disease (AD) and related neuropathological hallmarks. Numerous immunotherapeutic interventions have attempted to achieve adaptive immunity against A with a range of different antigenic designs and immunomodulatory strategies, most of them with great success in AD mouse model studies. Most of these studies have shown that both active and passive immunization can drastically reduce amyloid deposition and prevent the decline in cognitive performance. New approved clinical trials are under investigation to test the effectiveness of those different vaccination approaches, although previous data showed modest clinical success with some adverse inflammatory events in immunized elderly patients. The search for new approaches to overcome these severe side effects has led to novel technical methods such as live vector or DNA vaccines, although the use of innovative adjuvants combined with selected amyloid peptides is among the most auspicious. In this review, we compare and discuss the past and contemporary vaccines and the future strategies that may lead to a viable improvement in AD prevention and treatment.
Keywords: Alzheimer’s disease, vaccine, immunotherapy, animal models, neurodegeneration, amyloid-beta plaques.
Current Pharmaceutical Design
Title:Validating Immunotherapy in Alzheimer’s Disease: The EB101 Vaccine
Volume: 22 Issue: 7
Author(s): Ivan Carrera, Lucia Fernandez-Novoa, Gjumrakch Aliev, Carmen Vigo and Ramón Cacabelos
Affiliation:
Keywords: Alzheimer’s disease, vaccine, immunotherapy, animal models, neurodegeneration, amyloid-beta plaques.
Abstract: Vaccination has become one of the most promising immunotherapeutic approaches in the prevention and treatment of Alzheimer’s disease (AD) and related neuropathological hallmarks. Numerous immunotherapeutic interventions have attempted to achieve adaptive immunity against A with a range of different antigenic designs and immunomodulatory strategies, most of them with great success in AD mouse model studies. Most of these studies have shown that both active and passive immunization can drastically reduce amyloid deposition and prevent the decline in cognitive performance. New approved clinical trials are under investigation to test the effectiveness of those different vaccination approaches, although previous data showed modest clinical success with some adverse inflammatory events in immunized elderly patients. The search for new approaches to overcome these severe side effects has led to novel technical methods such as live vector or DNA vaccines, although the use of innovative adjuvants combined with selected amyloid peptides is among the most auspicious. In this review, we compare and discuss the past and contemporary vaccines and the future strategies that may lead to a viable improvement in AD prevention and treatment.
Export Options
About this article
Cite this article as:
Carrera Ivan, Fernandez-Novoa Lucia, Aliev Gjumrakch, Vigo Carmen and Cacabelos Ramón, Validating Immunotherapy in Alzheimer’s Disease: The EB101 Vaccine, Current Pharmaceutical Design 2016; 22 (7) . https://dx.doi.org/10.2174/1381612822666151209152204
DOI https://dx.doi.org/10.2174/1381612822666151209152204 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lipid-Activated Nuclear Receptors and Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Parkinson’s Disease: Is there a Role for Dietary and Herbal Supplements?
CNS & Neurological Disorders - Drug Targets Lymphocytic Choriomeningitis Virus Infection: Neglected Teratogenic Zoonosis
Current Women`s Health Reviews Drug Target in Eosinophilic Meningitis Caused by Angiostrongylus cantonensis
Infectious Disorders - Drug Targets Treatment of Central Nervous System Tuberculosis Infections and Neurological Complications of Tuberculosis Treatment
Current Pharmaceutical Design Emerging RNA-based Drugs: siRNAs, microRNAs and Derivates
Central Nervous System Agents in Medicinal Chemistry Immune Checkpoint Inhibitors and Neurotoxicity
Current Neuropharmacology Novel Applications of Nanotechnology in Controlling HIV and HSV Infections
Current Drug Research Reviews Commentary: Functional Neuronal CB2 Cannabinoid Receptors in the CNS
Current Neuropharmacology Models in Research of Pharmacoresistant Epilepsy: Present and Future in Development of Antiepileptic Drugs
Current Medicinal Chemistry Toll-Like Receptor System in the Human Endometrium
Current Immunology Reviews (Discontinued) Involvement of Toll-like Receptors in Ischemia-induced Neuronal Damage
Central Nervous System Agents in Medicinal Chemistry Ebola Virus Altered Innate and Adaptive Immune Response Signalling Pathways: Implications for Novel Therapeutic Approaches
Infectious Disorders - Drug Targets Immunomodulation in Trichinellosis: Does Trichinella Really Escape the Host Immune System?
Endocrine, Metabolic & Immune Disorders - Drug Targets Progress in Prevention of Mother-to-Child Transmission of HIV-1 in Zhejiang Province, China, 2007-2013
Current HIV Research Novel Targets in Multiple Sclerosis: To Oxidative Stress and Beyond
Current Topics in Medicinal Chemistry Targeting Strategies in Therapeutic Applications of Toxoplasmosis: Recent Advances in Liposomal Vaccine Delivery Systems
Current Drug Targets Transgenic Mouse Models of Alzheimer Disease: Developing a Better Model as a Tool for Therapeutic Interventions
Current Pharmaceutical Design Neurovirulence of SARS CoV2: From Clinical Data to Preclinical Neuropsychological Exploration
Coronaviruses Crosstalk between Gut Microbiota and the Central Nervous System in Multiple Sclerosis: Strengths, Weaknesses, Opportunities and Threats Analysis of the Use of An Experimental Model
CNS & Neurological Disorders - Drug Targets